

# Rachel L Tomko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5727329/publications.pdf>

Version: 2024-02-01

72  
papers

2,618  
citations

304743

22  
h-index

214800

47  
g-index

77  
all docs

77  
docs citations

77  
times ranked

3127  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reporting Treatment Fidelity in Behavioral Tobacco Treatment Clinical Trials: Scoping Review and Measurement Recommendations. <i>Nicotine and Tobacco Research</i> , 2022, 24, 150-159.	2.6	5
2	A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109311.	3.2	23
3	Parent-Child Concordance and Discordance in Family Violence Reporting: A Descriptive Analysis from the Adolescent Brain Cognitive Development Study. <i>Journal of Interpersonal Violence</i> , 2022, , 088626052210819.	2.0	0
4	Characterization of Salivary Progesterone in Female Smokers. <i>Nicotine and Tobacco Research</i> , 2022, 24, 1829-1833.	2.6	2
5	Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. <i>Addiction Biology</i> , 2021, 26, e12918.	2.6	9
6	Piloting of the Just Say Know prevention program: a psychoeducational approach to translating the neuroscience of addiction to youth. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 16-25.	2.1	10
7	Mobile, Remote, and Individual Focused: Comparing Breath Carbon Monoxide Readings and Abstinence Between Smartphone-Enabled and Stand-Alone Monitors. <i>Nicotine and Tobacco Research</i> , 2021, 23, 741-747.	2.6	13
8	Quantification of Smoking Characteristics Using Smartwatch Technology: Pilot Feasibility Study of New Technology. <i>JMIR Formative Research</i> , 2021, 5, e20464.	1.4	6
9	Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108815.	3.2	7
10	Racial Disparities in Elementary School Disciplinary Actions: Findings From the ABCD Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 998-1009.	0.5	24
11	Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109111.	3.2	13
12	Substance use patterns in 9-10 year olds: Baseline findings from the adolescent brain cognitive development (ABCD) study. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108946.	3.2	19
13	Passive Sensing of Preteens' Smartphone Use: An Adolescent Brain Cognitive Development (ABCD) Cohort Substudy. <i>JMIR Mental Health</i> , 2021, 8, e29426.	3.3	17
14	The estimand framework and its application in substance use disorder clinical trials: a case study. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 658-663.	2.1	1
15	Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. <i>Nicotine and Tobacco Research</i> , 2020, 22, 81-88.	2.6	19
16	Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. <i>Psychopharmacology</i> , 2020, 237, 479-490.	3.1	14
17	Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1374-1382.	2.6	23
18	The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. <i>Psychopharmacology</i> , 2020, 237, 543-555.	3.1	17

#	ARTICLE	IF	CITATIONS
19	Impact of disaster exposure severity: Cascading effects across parental distress, adolescent PTSD symptoms, as well as parent-child conflict and communication. <i>Social Science and Medicine</i> , 2020, 264, 113293.	3.8	13
20	Remote Methods for Conducting Tobacco-Focused Clinical Trials. <i>Nicotine and Tobacco Research</i> , 2020, 22, 2134-2140.	2.6	44
21	Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. <i>Psychoneuroendocrinology</i> , 2020, 120, 104752.	2.7	9
22	Making pharmacotherapy trials for substance use disorder more efficient: Leveraging real-world data capture to maximize power and expedite the medication development pipeline. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107897.	3.2	11
23	Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. <i>Frontiers in Endocrinology</i> , 2020, 11, 549928.	3.5	45
24	An electronic, smart lighter to measure cigarette smoking: A pilot study to assess feasibility and initial validity. <i>Addictive Behaviors</i> , 2019, 98, 106052.	3.0	18
25	Efficacy and Safety of Varenicline for Adolescent Smoking Cessation. <i>JAMA Pediatrics</i> , 2019, 173, 1146.	6.2	26
26	Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies. <i>Current Psychiatry Reports</i> , 2019, 21, 96.	4.5	38
27	Methods to reduce the incidence of false negative trial results in substance use treatment research. <i>Current Opinion in Psychology</i> , 2019, 30, 35-41.	4.9	9
28	Pharmacological Treatment of Youth Substance Use Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 559-572.	1.3	44
29	Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. <i>Drug and Alcohol Dependence</i> , 2019, 198, 105-111.	3.2	11
30	Behavioral Treatments for Adolescent Cannabis Use Disorder: a Rationale for Cognitive Retraining. <i>Current Addiction Reports</i> , 2019, 6, 437-442.	3.4	6
31	Measuring Within-Individual Cannabis Reduction in Clinical Trials: a Review of the Methodological Challenges. <i>Current Addiction Reports</i> , 2019, 6, 429-436.	3.4	9
32	Cannabis Use Disorder as a Developmental Disorder. , 2019, , 189-199.		5
33	Tobacco and cannabis co-use and interrelatedness among adults. <i>Addictive Behaviors</i> , 2019, 90, 354-361.	3.0	41
34	Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 26-41.	2.1	26
35	Tobacco and cannabis co-use: Drug substitution, quit interest, and cessation preferences.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 265-275.	1.8	38
36	Medical Cannabis Use among Adults in the Southeastern United States. , 2019, 2, 53-65.		17

#	ARTICLE	IF	CITATIONS
37	Medical Cannabis Use among Adults in the Southeastern United States. Cannabis (Research Society on) Tj ETQq1 1,0,784314,rgBT /Cve	0.6	10
38	The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug and Alcohol Dependence, 2018, 185, 17-22.	3.2	39
39	Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug and Alcohol Dependence, 2018, 182, 1-7.	3.2	30
40	Introduction to the special issue: Utilizing ambulatory assessment to better understand the etiology, maintenance, treatment, and remission of addictive disorders. Addictive Behaviors, 2018, 83, 1-4.	3.0	3
41	Solving the problem of cannabis quantification. Lancet Psychiatry,the, 2018, 5, e8.	7.4	17
42	Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug and Alcohol Dependence, 2018, 192, 59-66.	3.2	21
43	The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Addictive Behaviors, 2018, 85, 26-30.	3.0	16
44	Acceptability and compliance with a remote monitoring system to track smoking and abstinence among young smokers. American Journal of Drug and Alcohol Abuse, 2018, 44, 561-570.	2.1	21
45	Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. International Review of Psychiatry, 2018, 30, 216-225.	2.8	17
46	-acetylcysteine: A potential treatment for substance use disorders. Current Psychiatry, 2018, 17, 30-36, 41-42, 55.	1.7	14
47	Countering Craving with Disgust Images: Examining Nicotine Withdrawn Smokersâ€™™ Motivated Message Processing of Anti-Tobacco Public Service Announcements. Journal of Health Communication, 2017, 22, 254-261.	2.4	35
48	A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 2017, 177, 249-257.	3.2	109
49	Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. Journal of Substance Abuse Treatment, 2017, 81, 53-58.	2.8	88
50	Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology, 2017, 234, 427-435.	3.1	19
51	Integrated Treatment of PTSD and Substance Use Disorders: The Mediating Role of PTSD Improvement in the Reduction of Depression. Journal of Clinical Medicine, 2017, 6, 9.	2.4	7
52	The Effects of a <b><i>BDNF</i></b> Val66Met Polymorphism on Posttraumatic Stress Disorder: A Meta-Analysis. Neuropsychobiology, 2017, 76, 136-142.	1.9	18
53	Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addictive Behaviors, 2016, 63, 172-177.	3.0	23
54	Personalizing substance use treatment based on pre-treatment impulsivity and sensation seeking: A review. Drug and Alcohol Dependence, 2016, 167, 1-7.	3.2	38

#	ARTICLE	IF	CITATIONS
55	The structure of the UPPS-R-Child impulsivity scale and its relations with substance use outcomes among treatment-seeking adolescents. <i>Drug and Alcohol Dependence</i> , 2016, 161, 276-283.	3.2	19
56	Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder. <i>Journal of Substance Abuse Treatment</i> , 2016, 63, 72-77.	2.8	22
57	Negative Affect Instability Among Individuals With Comorbid Borderline Personality Disorder and Posttraumatic Stress Disorder. <i>Clinical Psychological Science</i> , 2016, 4, 67-81.	4.0	24
58	Undifferentiated negative affect and impulsivity in borderline personality and depressive disorders: A momentary perspective.. <i>Journal of Abnormal Psychology</i> , 2015, 124, 740-753.	1.9	72
59	Measuring impulsivity in daily life: The Momentary Impulsivity Scale.. <i>Psychological Assessment</i> , 2014, 26, 339-349.	1.5	110
60	Social Context of Anger in Borderline Personality Disorder and Depressive Disorders: Findings From a Naturalistic Observation Study. <i>Journal of Personality Disorders</i> , 2014, 28, 434-448.	1.4	18
61	Characteristics of Borderline Personality Disorder in a Community Sample: Comorbidity, Treatment Utilization, and General Functioning. <i>Journal of Personality Disorders</i> , 2014, 28, 734-750.	1.4	342
62	Does Hangover Influence the Time to Next Drink? An Investigation Using Ecological Momentary Assessment. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1461-1469.	2.4	35
63	Recall of Expressed Affect During Naturalistically Observed Interpersonal Events in Those With Borderline Personality Disorder or Depressive Disorder. <i>Assessment</i> , 2014, 21, 73-81.	3.1	14
64	Substance Use Disorders and Personality Disorders. , 2014, , .		2
65	Gene-Environment Studies and Borderline Personality Disorder: A Review. <i>Current Psychiatry Reports</i> , 2013, 15, 336.	4.5	36
66	The influence of general identity disturbance on reports of lifetime substance use disorders and related outcomes among sexual minority adults with a history of substance use.. <i>Psychology of Addictive Behaviors</i> , 2011, 25, 530-541.	2.1	20
67	Affect and alcohol use: An ecological momentary assessment study of outpatients with borderline personality disorder.. <i>Journal of Abnormal Psychology</i> , 2011, 120, 572-584.	1.9	95
68	Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity.. <i>Journal of Abnormal Psychology</i> , 2011, 120, 656-669.	1.9	65
69	Borderline Personality Disorder in 3-D: Dimensions, Symptoms, and Measurement Challenges. <i>Social and Personality Psychology Compass</i> , 2010, 4, 1057-1069.	3.7	22
70	Longitudinal Associations in Borderline Personality Disorder Features: Diagnostic Interview for Borderlinesâ€”Revised (DIB-R) Scores Over Time. <i>Journal of Personality Disorders</i> , 2010, 24, 377-391.	1.4	14
71	Revised NESARC Personality Disorder Diagnoses: Gender, Prevalence, and Comorbidity with Substance Dependence Disorders. <i>Journal of Personality Disorders</i> , 2010, 24, 412-426.	1.4	536
72	Characteristics of Borderline Personality Disorder in a Community Sample: Comorbidity, Treatment Utilization, and General Functioning. <i>Journal of Personality Disorders</i> , 0, , 1-17.	1.4	11